Exela Pharma Drug Patent Portfolio
Exela Pharma owns 2 orange book drugs protected by 17 US patents Given below is the list of Exela Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10478453 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10583155 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10653719 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10905713 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10905714 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10912795 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10918662 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10933089 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11510941 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11510942 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11642370 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11648262 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11679125 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11684636 | Stable, highly pure l-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11826383 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11969439 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US9486530 | Ganciclovir compositions and related methods | 02 Sep, 2034 | Active |
Latest Legal Activities on Exela Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Exela Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 01 Jul, 2024 | US9486530 |
| Petition Requesting Trial | 13 Feb, 2024 | US11642370 |
|
Email Notification
Critical
| 29 Nov, 2023 | US11826383 |
| Recordation of Patent eGrant | 28 Nov, 2023 | US11826383 |
|
Application ready for PDX access by participating foreign offices
Critical
| 28 Nov, 2023 | US11826383 |
|
Recordation of Patent Grant Mailed
Critical
| 28 Nov, 2023 | US11826383 |
| Mail Patent eGrant Notification | 28 Nov, 2023 | US11826383 |
| Patent eGrant Notification | 28 Nov, 2023 | US11826383 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 28 Nov, 2023 | US11826383 |
|
Email Notification
Critical
| 09 Nov, 2023 | US11826383 |
|
Issue Notification Mailed
Critical
| 08 Nov, 2023 | US11826383 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Nov, 2023 | US10653719 |
| Dispatch to FDC | 31 Oct, 2023 | US11826383 |
|
Application Is Considered Ready for Issue
Critical
| 31 Oct, 2023 | US11826383 |
|
Issue Fee Payment Verified
Critical
| 10 Oct, 2023 | US11826383 |
Exela Pharma's Drug Patent Litigations
Exela Pharma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 19, 2020, against patent number US10478453. The petitioner Eton Pharmaceuticals, Inc., challenged the validity of this patent, with Exela Pharma Sciences, LLC as the respondent. Click below to track the latest information on how companies are challenging Exela Pharma's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11642370 | February, 2024 |
Institution Denied
(08 Aug, 2024)
| Exela Pharma Sciences, LLC | Nexus Pharmaceuticals LLC |
| US10653719 | September, 2020 |
Institution Denied
(23 Apr, 2021)
| Exela Pharma Sciences LLC | Eton Pharmaceuticals, Inc. |
| US10583155 | June, 2020 |
Terminated-Denied
(15 Dec, 2020)
| Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
| US10478453 | May, 2020 |
Institution Denied
(18 Nov, 2020)
| Exela Pharma Sciences, LLC | Eton Pharmaceuticals, Inc. |
Exela Pharma's Family Patents
Exela Pharma Drug List
Given below is the complete list of Exela Pharma's drugs and the patents protecting them.
1. Elcys
Elcys is protected by 16 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10478453 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10583155 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10653719 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10905713 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10905714 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10912795 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10918662 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10933089 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11510941 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11510942 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11642370 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11648262 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11679125 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11684636 | Stable, highly pure l-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11826383 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11969439 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Elcys's drug page
2. Ganzyk-rtu
Ganzyk-rtu is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9486530 | Ganciclovir compositions and related methods |
02 Sep, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ganzyk-rtu's drug page